Ilan Zipkin
Senior Investment Director @ Takeda Ventures
Palo Alto, United States
Ilan Zipkin is a Series A investor at Takeda Ventures in Palo Alto focused on Biotechnology and Health Care. Ilan Zipkin is the Partner and VP, Business Development and Licensing at Aditum Bio. She attended University of California, San Francisco.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Ilan Zipkin invests in
Stages Ilan Zipkin invests in
Countries Ilan Zipkin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 5 (83%)
- Health Care 4 (67%)
- Therapeutics 2 (33%)
- Pharmaceutical 2 (33%)
- Medical 1 (17%)
Stage
- Series A 3 (50%)
- Series C 1 (17%)
- Debt Financing 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- United States 3 (50%)
- Canada 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $8M / Debt Financing / Apr 14, 2017 | ||
| Bioniz is an emerging biotechnology/drug development company focused on discovering small peptides and molecules for the treatment of autoimmune diseases and some forms of cancer. Bioniz mission is to complete proof of concept and preclinical studies of its lead technology and seek partners to conduct clinical trials for regulatory approvaland commercialization.At Bioniz, they are committed to the discovery of novel molecules that enhance the lives of people across the globe. They perform our research with integrity and conscious, and bear in mind always our responsibility to the public health and their investors.It was founded in 2009 and headquartered in Irvine, California. | $13M / Series A / Aug 01, 2016 | ||
| Cortexyme is a clinical stage pharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific, undisclosed pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is currentlytesting several potential lead therapeutics in preclinical studies. | $15M / Series A / Jan 06, 2016 | ||
| Encycle Therapeutics is a Toronto-based biotech company exploiting a unique platform technology that enables the rapid synthesis of drug-like macrocycles or membrane-permeable nacellins. Nacellins have enormous potential to target intracellular protein-protein interactions, which are largely intractable to small molecule and biologic modulation,and can represent cheaper, oral equivalents to existing biologics (e.g., monoclonal antibodies). Encycle has collaborated with several pharmaceutical companies to complete a screening library of nacellins, many of which are cell-permeable and possess other drug-like properties. The company is also pursuing independent development of nacellins against integrin alpha-4-beta-7 (IBD) and SMURF2 (fibrosis); its lead program seeks to develop orally bioavailable inhibitors of integrin alpha-4-beta-7, which are safer and less immunogenic than marketed and investigational biologics targeting the same protein. | $2.1M / Venture - Series Unknown / Sep 30, 2015 | ||
| VHsquared is dedicated to the development of novel antibody domains engineered to be stable in the GI tract.Their novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases.There has been an explosion of interest in foods that haveadditional physiological benefits.VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the GI mucosal interface harnessing recent technological developments, including analysis of the microbiota and advances in mucosal immunology.Conventional antibodies are degraded in the gut and therefore efficacy obtained from oral administration is limited. VHsquared uses domain antibodies that can be selected and engineered to resist degradation, are intrinsically very stable and are locally active in the gastrointestinal tract.Products will offer advantages in terms of specificity, safety, efficacy, convenience and cost. | Series A / Dec 30, 2013 | ||
| Somaxon Pharmaceuticals is a growing specialty pharmaceutical company dedicated to commercializing proprietary branded prescription therapeutics to treat important medical conditions where there is an unmet medical need and/or high-level of patient dissatisfaction. The company currently is focusing on in-licensing, developing and marketingproprietary products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area.Somaxon currently is promoting Silenor®, the first and only nonscheduled prescription medication approved for the treatment of sleep maintenance insomnia. Silenor is now available for prescription in the United States. | $65M / Series C / Jun 06, 2005 |
Co-Investors
About Takeda Ventures
Takeda Ventures, Inc. (TVI) is the corporate investment arm of Takeda Pharmaceutical Company Limited (TPC). TVI was founded in 2001 and invests in current and future areas of interest for TPC. They are based alongside Takeda’s R&D sites in Cambridge, MA, and San Diego, CA. As a strategic investor, TVI aims to provide support and guidance toentrepreneurs and early-stage companies driving concepts through clinical proof of concept. They also strive to forge active, collaborative interactions that result in synergies with Takeda's considerable R&D resources. Their goal is to build a portfolio of strategic investments, with an immediate emphasis on oncology, gastroenterology, neuroscience, and rare diseases.
Takeda Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Michael Martin
Head of Takeda Ventures, Inc.
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Ilan Zipkin invest in?
Ilan Zipkin invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Ilan Zipkin?
Public channels for Ilan Zipkin include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Ilan Zipkin last invest?
The most recent investment recorded for Ilan Zipkin closed in Apr 2017. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
